These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27282618)

  • 21. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners.
    Gietel-Habets JJ; de Die-Smulders CE; Derks-Smeets IA; Tibben A; Tjan-Heijnen VC; van Golde R; Gomez-Garcia E; Kets CM; van Osch LA
    Hum Reprod; 2017 Mar; 32(3):588-597. PubMed ID: 28073972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result.
    Brédart A; Kop JL; De Pauw A; Caron O; Fajac A; Noguès C; Stoppa-Lyonnet D; Dolbeault S
    Breast; 2017 Feb; 31():121-127. PubMed ID: 27837705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
    Jeffers L; Morrison PJ; McCaughan E; Fitzsimons D
    Eur J Oncol Nurs; 2014 Aug; 18(4):411-8. PubMed ID: 24731853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
    Nippert I; Schlegelberger B;
    Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics.
    Schott S; Vetter L; Keller M; Bruckner T; Golatta M; Eismann S; Dikow N; Evers C; Sohn C; Heil J
    Arch Gynecol Obstet; 2017 Jun; 295(6):1451-1458. PubMed ID: 28439664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does enhanced information at cancer genetic counseling improve counselees' knowledge, risk perception, satisfaction and negotiation of information to at-risk relatives?--a randomized study.
    Roshanai AH; Rosenquist R; Lampic C; Nordin K
    Acta Oncol; 2009; 48(7):999-1009. PubMed ID: 19636983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "It's not if I get cancer, it's when I get cancer": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk.
    Dean M
    Soc Sci Med; 2016 Aug; 163():21-7. PubMed ID: 27376595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
    Brédart A; Kop JL; Dick J; Cano A; De Pauw A; Anota A; Brunet J; Devilee P; Stoppa-Lyonnet D; Schmutzler R; Dolbeault S
    BMJ Open; 2019 Sep; 9(9):e029926. PubMed ID: 31551380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact.
    Wevers MR; Hahn DE; Verhoef S; Bolhaar MD; Ausems MG; Aaronson NK; Bleiker EM
    Patient Educ Couns; 2012 Oct; 89(1):89-95. PubMed ID: 22543000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
    Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Factors for Distress After Genetic Testing for Hereditary Cancer.
    Voorwinden JS; Jaspers JP
    J Genet Couns; 2016 Jun; 25(3):495-503. PubMed ID: 26475052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada.
    Raphael J; Verma S; Hewitt P; Eisen A
    J Genet Couns; 2016 Dec; 25(6):1309-1316. PubMed ID: 27228984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
    Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
    Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.